Hawaii Biotech Receives Approval for West Nile Vaccine Trial
Posted on: Monday, 7 January 2008, 09:00 CST
Hawaii Biotech has received FDA's approval to initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine.
The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding to complete the trial. Depending on the actual start date, results of the trial may be available by the end of 2008.
Carolyn Weeks-Levy, president and CEO of HBI, said: "The West Nile vaccine will be the first candidate to enter clinical trials for Hawaii Biotech. This is a substantial milestone for the company as it is a novel vaccine candidate with which the FDA has had little experience."
Source: Datamonitor
Related Articles
- Hawaii Biotech Receives Funding From the Pediatric Dengue Vaccine Initiative
- VaxGen Publishes Results of Phase I Clinical Trial of Anthrax Vaccine Candidate
- Sanofi Bird Flu Vaccine Trial Encouraging: Study
- Bird flu vaccine trial encouraging: study
- Avantogen and Hawaii Biotech Combine Vaccine Businesses; World-Class Vaccine Developer is Created to Accelerate Pandemic Influenza, West Nile and Dengue Fever Vaccine Programs
- India's AIDS vaccine trials enter crucial stage
- Vical DNA Vaccine Technology Enters Phase 2 Clinical Trial for HIV
- Russia Likely to Have Bird Flu Vaccine By Yearend
- Trial Vaccine Effective Against Dog Malady
- Trial Vaccine Might Reduce Risk of Cervical Cancer
 |
 |
User Comments (0)
RSS Feeds